

Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies

Published: 2012-MAY-01

Pages: 6588

Format: PDF

Price: 4495 USD (Single User License)

Description

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Angiogenesis

The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.

This part is based on the following publication:

Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part II: Protein Kinase Inhibitors

The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.

This part is based on the following publication:

Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

Part III: Antibodies

The cancer antibody drug report part comprises defined and up to date development strategies for 531 antibody drugs in oncology within the portfolio of 196 companies world-wide, from Ceased to Marketed. The report extensively analyses their 255 identified drug targets, organized into 266 drug target strategies, and assesses them in 75 cancer indications.

This part is based on the following publication:

The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

- * Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- * Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
- * Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- * Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Table of Contents

Key Topics Covered:

Part I: Angiogenesis

5.1	The Scope of this Report	37
6	Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets)	41-421
7	Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs)	424-666
8	Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies)	667-709
9	Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications)	710-848
10	Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs)	849-1685
12	Drug Index	1687
13	Company Index	1697

Figures: Includes 7 Figures

Tables: Includes 310 Tables

Total Number of Pages: 1,704

Part II: Protein Kinase Inhibitors

5.1	The Scope of this Report	38
6	Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets)	42-516
7	Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs)	517-945
8	Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies)	946-1013
9	Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications)	1014-1223
10	Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs)	1224-2939
11	Disclaimer	2940

Figures: Includes 8 Figures

Tables: Includes 389 Tables

Total Number of Pages: 2,940

Part III: Antibodies

5.1	The Scope of this Report	35
6	Consider the Therapeutic Target Among Antibody Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (255 Drug Targets)	39-430
7	Emerging New Products to Established Ones: Drug Target Strategies of Antibody Drugs in Oncology by their Highest Stage of Development (266 Drug Targets Strategies and 531 Antibody Drugs)	431-768
8	Selecting Cancer Indication for Antibody Drugs (75 Cancer Indications)	769-893
9	Pipeline and Portfolio Planning: Competitive Benchmarking of the Antibody Drug Pipeline in Oncology by Investigator (196 Investigators and 531 Antibody Drugs)	894-1,916
10	Disclaimer	1917
11	Drug Index	1918
12	Company Index	1934

Figures: Includes 5 Figures

Tables: Includes 347 Tables

Total Number of Pages: 1,944

Ordering

Order Online - <http://www.biomarketgroup.com/market-research-report/triple-analysis-angiogenesis-protein-kinase-inhibitors-and-antibodies.html>

Order by Fax - using the form below

Order by Post - print the order form below and send to:

<http://www.biomarketgroup.com>

BioMarket Group - A Global Online Aggregator of Life Science Market Research

BioMarket Group
Björnnäsvägen 21
11419 STOCKHOLM
SWEDEN

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to +46-8-56849191. If you have any questions please visit

<http://www.biomarketgroup.com/market-research-report/contacts/>

Order Information

Please verify that the product information is correct:

Product Name: **Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies**

Web Address: <http://www.biomarketgroup.com/market-research-report/triple-analysis-angiogenesis-protein-kinase-inhibitors-and-antibodies.html>

Format: PDF

Price: 4495 USD (Single User License)

Delivery of hard copy or CD-ROM is subject to a Courier charge of 50 USD.

Delivery within Sweden is subject to VAT at 25%.

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: _____

Name: _____

Email Address:* _____

Job Title: _____

Organization: _____

EU companies must supply: VAT / BTW / MOMS

MWST / IVA / FPA number:

Address: _____

Zip Code: _____

City: _____

State: _____

Country: _____

Phone Number: _____

Fax Number: _____

Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:**
- American Express
 - Master Card
 - Visa

Cardholder Name: _____

Expiry Date (MM/YY): _____

Card Number: _____

CVV Number: _____

- Pay by check:**

Please post the check, accompanied by this form, to:

BioMarket Group
Björnnäsvägen 21
11419 STOCKHOLM
SWEDEN

- Pay by wire transfer:** Please transfer funds to:

Account number: 43521169

Swift code: HANDSESS

IBAN number: SE74 6000 0000 0000 4352 1169

Bank Address: Handelsbanken, Stockholm, Sweden

If you have a Marketing Code please enter it below:

Marketing Code: _____

Please supply purchase order number if needed:

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, Gmail)

Please note that by ordering from BioMarket Group you are agreeing to our Terms and Conditions at

<http://www.biomarketgroup.com/market-research-report/biomarket-group-full-terms-and-conditions/>

Please fax this form to: +46-8-56849191